Prospective, Multicentre, Randomized, Controlled, Cross-over Study on the Safety and Performance of the Biologic Fusion Option of DialogiQ Compared to Haemodialysis Without Biologic Fusion in Hypotension Prone Patients on Maintenance Haemodialysis

Inclusion Criteria: * Male or female subjects ≥18 years of age * Chronic bicarbonate standard high-flux haemodialysis or hemodiafiltration for at least 3 months * Dialysis frequency 3 x per week * Dialysis duration per session ≥ 4h * Patient on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes * No residual renal function (definition: ≤100 ml urine/day) - changed to "No to minimal residual renal function (definition: ≤ 300 ml/day)" with Amendment 1 (CIP version 6) * Stable dry body weight for at least 4 weeks * Subjects who are willing to give a voluntary consent to participate in the study Exclusion Criteria: * Simultaneous participation in another interventional clinical trial (drugs or medical devices studies) * Vascular access insufficiency (mean blood flow \<200ml/min) * Patients treated with dialysis profiles: sodium profile, Ultrafiltration (UF) profile, and temperature profile - changed to: " Patients treated with dialysis profiles during the 9 prescreening visits: sodium profile, UF profile, and temperature profile. However, patients on sodium, ultrafiltration or temperature profiling expected to reduce intradialytic hypotensive episodes can be evaluated for enrollment when their frequency of sessions complicated by hypotension demonstrate the lack of efficacy of the applied profiles" with Amendment 1 (CIP version 6) * Use of the BioLogic fusion function during the last 9 dialysis sessions recorded at the site (retrospective screening period…